Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Martin, Guiterrez"'
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Baseline (screening) vs treatment cycle 2 (P=.06; paired t test). For patient 5, baseline data were not available.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcd98b63eb49f579d01cbe44a0a85231
https://doi.org/10.1158/1078-0432.22475423
https://doi.org/10.1158/1078-0432.22475423
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Purpose:Assess safety and efficacy of nivolumab plus nab-paclitaxel and gemcitabine in patients with locally advanced/metastatic pancreatic cancer in a two-part, open-label, phase I trial.Patients and Methods:Fifty chemotherapy-naive patients receive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91944ff29f7b99aa8e56f618a1dd6950
https://doi.org/10.1158/1078-0432.c.6529076.v1
https://doi.org/10.1158/1078-0432.c.6529076.v1
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Percentage lymphocyte subset Ki67+. All patient visits are binned by treatment cycle. Data at baseline and treatment cycle 3 were compared using the Wilcoxon signed rank test. All available data are illustrated; however, statistical comparisons were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af451ccc2b3f88d0ca2643cefe85947
https://doi.org/10.1158/1078-0432.22475429
https://doi.org/10.1158/1078-0432.22475429
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
T-Cell Tumor Infiltration in Tissue-Matched Baseline (screening) and On-Treatment Metastatic Tumors (arm B parts 1 and 2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5462aa83ef7e3c2c1c1145183bef1b4
https://doi.org/10.1158/1078-0432.22475426
https://doi.org/10.1158/1078-0432.22475426
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Investigator-assessed PFS and OS in patients with PD-L1 expression cutoff of 1% (A, B) or 5% (C, D). HR, hazard ratio; mo, months; OS, overall survival; PD-L1, programmed cell death ligand-1; PFS, progression-free survival.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46e9db745e67db99e4742619e1ece12c
https://doi.org/10.1158/1078-0432.22475435.v1
https://doi.org/10.1158/1078-0432.22475435.v1
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Patients were enrolled in Arm B Part 1 after the safety oversight committee deemed Arm A Part 1 safe. DRC, data review committee; LAPC, locally advanced pancreatic cancer; MPC, metastatic pancreatic cancer; RP2D, recommended Part 2 dose.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898ef1dea38981f86f8ebf1a7d51ab9a
https://doi.org/10.1158/1078-0432.22475438
https://doi.org/10.1158/1078-0432.22475438
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Concentrations of CXCL10 (A) and sIL2Rα (B) at baseline and peak on-treatment values. Investigator-assessed PFS in patients with high or low serum cytokines CXCL10 (C) and sIL2Rα (D). CXCL10, interferon gamma-induced protein 10; mo, months; NE, not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b40b6e000cad2b036744f48c00548a3
https://doi.org/10.1158/1078-0432.22475420.v1
https://doi.org/10.1158/1078-0432.22475420.v1
Autor:
Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg
Data Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::647d7db3c6ca7c20467ff73cc4468883
https://doi.org/10.1158/1078-0432.22475417
https://doi.org/10.1158/1078-0432.22475417
Autor:
Larry Lyons, Martin Guiterrez, Aparna Kaylan, Sibabrata Banerjee, Rafia Bhore, Teng Jin Ong, David M. Waterhouse, Chrystal U. Louis, Daniel W. Pierce, Ben George, Rishi Jain, Edward J. Kim, Hatem Soliman, Daniel R. Carrizosa, Thomas Lila, David J. Reiss, Zev A. Wainberg, Aparna Raj Parikh, Peter J. O'Dwyer, E. Gabriela Chiorean, Howard S. Hochster
Publikováno v:
Clinical Cancer Research. 26:4814-4822
Purpose: Assess safety and efficacy of nivolumab plus nab-paclitaxel and gemcitabine in patients with locally advanced/metastatic pancreatic cancer in a two-part, open-label, phase I trial. Patients and Methods: Fifty chemotherapy-naive patients rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12f33021c723a539fb9e4bf7ef200fc4
https://doi.org/10.1158/1078-0432.ccr-20-0099
https://doi.org/10.1158/1078-0432.ccr-20-0099
Autor:
Zev A, Wainberg, Howard S, Hochster, Edward J, Kim, Ben, George, Aparna, Kaylan, E Gabriela, Chiorean, David M, Waterhouse, Martin, Guiterrez, Aparna, Parikh, Rishi, Jain, Daniel Ricardo, Carrizosa, Hatem H, Soliman, Thomas, Lila, David J, Reiss, Daniel W, Pierce, Rafia, Bhore, Sibabrata, Banerjee, Larry, Lyons, Chrystal U, Louis, Teng Jin, Ong, Peter J, O'Dwyer
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(18)
Assess safety and efficacy of nivolumab plusFifty chemotherapy-naive patients receivedOne DLT (hepatitis) was reported in part 1 among six DLT-evaluable patients; 48 of 50 patients experienced grade 3/4 TEAEs and 18 discontinued treatment due to TEAE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a44d6bbcf116dda625f5c327a64e637
https://pubmed.ncbi.nlm.nih.gov/32554514
https://pubmed.ncbi.nlm.nih.gov/32554514